Traditionally, patients undergoing TAVI are treated with dual antiplatelet therapy (DAPT). This strategy in not based on strong evidence.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation
May 22, 2014
St. Jude Medical Announces First Implants in US Study of the Portico Transcatheter Aortic Heart Valve System
May 21, 2014
The PORTICO trial has opened to evaluate the Portico Transcatheter Aortic Valve System. This prospective multicenter trial involving up to 40 sites will randomize pts to Portico vs another TAVR valve in the US.
Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score
May 9, 2014
The FRANCE 2 investigators have developed a scoring system to predict the risk of in-hospital or 30-day mortality for patients undergoing TAVI. There were 3833 TAVIs used for development and validation of the scoring system with the majority of patients receiving an Edwards Sapien prosthesis.
First Bioprosthesis Thrombosis After Transcatheter Mitral Valve-in-Valve Implantation: Diagnosis and Treatment
May 8, 2014
An interesting case that raises the question of the need for anticoagulation in patients treated with a transcatheter valve in valve in mitral position
April 28, 2014
Dr. Thomas Walther discusses the transapical TAVR Access technique at Dallas-Leipzig Valve 2012.
April 21, 2014
This article on Type A Aortic Dissection was selected as a top article from 2013 by the 2014 Circulation editors. The original article is here: http://circ.ahajournals.org/content/128/15/1602.full?sid=a7153f9d-9551-4...
April 10, 2014
This article describes a standardized and reproducible trans-aortic TAVR approach with the Edwards Sapien valve and Ascendra 3 delivery system.
April 9, 2014
Authors compared transcatheter aortic–valve replacement (TAVR), using a self–expanding transcatheter aortic–valve bioprosthesis, with surgical aortic–valve replacement in patients with severe aortic stenosis and an increased risk of death during surgery.
Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation
April 9, 2014
In this study the authors looked at the impact of coronary artery disease (CAD) in a single series of 445 patients undergoing TAVI for aortic valve stenosis. The pre-established primary endpoint of the study was a composite of cardiovascular death, stroke, or myocardial infarction (MI)—at 1 year.